WJ+ Wharton's Jelly
A concentrated umbilical cord Wharton's Jelly product with live cells kept in the native Wharton's Jelly matrix. For non-IV procedures only.
Product illustration. Photos available on request. Actual packaging may differ.
WJ+ diluted to one-quarter of the starting tissue weight. A lower-concentration birth-tissue product that the manufacturer positions as an alternative to PRP workflows.
Part of the biologics line. Compare all 11 products by type, format, and storageCommon in: Orthopedics · Aesthetics · Practices comparing PRP options
| Per 3 mL (approx.) | ~500,000 total viable nucleated cells · ~65,000 MSCs · ~90,000 EPCs · ~25 million exosomes |
|---|---|
| Size | 3 mL |
From Comprehensive Biosciences materials. Confirm current specs and IFU before use.
Biotechnology company founded in 2022 and led by Dr. Charles Sly and Dr. Roy Korth, with patented methods for isolating serum components and perinatal tissue. Its birth-tissue line comes from a manufacturer-owned, FDA-registered tissue bank: Wharton's Jelly, exosomes, Muse cell products, cord blood plasma extract, and Bio Scaffolding.
A concentrated umbilical cord Wharton's Jelly product with live cells kept in the native Wharton's Jelly matrix. For non-IV procedures only.
WJ+ with the live cells removed, keeping the growth factors, hyaluronic acid, exosomes, and ECM proteins. A cell-free option for non-IV procedures.
Wharton's Jelly allografts from umbilical cords donated by consenting mothers. The two versions use the same processing and differ only in concentration.